Lamivudine/Zidovudine Teva (lamivudine;zidovudine)
Generic
- Region
- 🇪🇺 EU
- Active substance
- lamivudine;zidovudine
- Company
- Teva Pharma B.V.
- Status
- Withdrawn
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 18 Nov 2010
- EU approval
- Mon 28 Feb 2011
- Designations
- Generic
- Application
- EMEA/H/C/001236
- ATC
- J05AR01
- Official record
- www.ema.europa.eu
Indication
Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Trizivir Withdrawn · ViiV Healthcare BV
- 🇪🇺 Combivir Authorised · ViiV Healthcare BV
Follow Lamivudine/Zidovudine Teva
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.